Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside
Viking Therapeutics shares closed at $33.53 Friday, near recent highs after rebounding from a 40% drop in August. Its obesity drug VK2735 showed 12.2% weight loss in a Phase 2 trial but had a 20% dropout rate from side effects. Analysts see Viking as a possible acquisition target amid recent industry deals. The company holds over $800 million in cash and reports Q3 earnings on Oct. 22.